The Claim
18F-PSMA-1007 PET/CT detects pelvic lymph node metastases in 87% of men with unfavorable intermediate- or high-risk prostate cancer, significantly outperforming whole-body MRI with DWI (45%) and contrast-enhanced CT (26%) in sensitivity, while maintaining high specificity (96–98%), enabling more accurate initial staging by identifying metastases in lymph nodes smaller than 8 mm that are invisible to anatomical imaging.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
A new kind of scan called 18F-PSMA-1007 PET/CT is much better at finding tiny cancer spread in the pelvis than older scans like MRI or CT — it catches cancer in nearly 9 out of 10 men where other scans miss it, and it can see really small tumors that regular scans can’t even spot.
See the scientific wording
18F-PSMA-1007 PET/CT detects pelvic lymph node metastases in 87% of men with unfavorable intermediate- or high-risk prostate cancer, significantly outperforming whole-body MRI with DWI (45%) and contrast-enhanced CT (26%) in sensitivity, while maintaining high specificity (96–98%), enabling more accurate initial staging by identifying metastases in lymph nodes smaller than 8 mm that are invisible to anatomical imaging.
What the research says
1 studyThis study found that the 18F-PSMA-1007 PET/CT scan found prostate cancer spread to nearby lymph nodes much better than MRI or CT scans, especially in tiny nodes others couldn’t see — exactly what the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.